Catalent Inc. (NYSE:CTLT) had its price objective upped by Jefferies Group from $25.00 to $28.00 in a research report sent to investors on Thursday morning, StockTargetPrices.com reports. The firm currently has a hold rating on the stock.
Several other brokerages have also commented on CTLT. Bank of America Corp. upgraded Catalent from a neutral rating to a buy rating in a research note on Monday, June 20th. Wells Fargo & Co. upgraded Catalent from a market perform rating to an outperform rating in a research note on Tuesday, June 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $27.83.
Catalent (NYSE:CTLT) traded up 0.39% during trading on Thursday, reaching $25.70. 263,626 shares of the company’s stock traded hands. The company has a 50 day moving average of $25.21 and a 200 day moving average of $25.67. Catalent has a one year low of $18.92 and a one year high of $32.24. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of 28.88 and a beta of 1.41.
A number of institutional investors have recently bought and sold shares of CTLT. M&T Bank Corp bought a new position in Catalent during the first quarter valued at about $207,000. Forward Management LLC raised its position in Catalent by 8.7% in the first quarter. Forward Management LLC now owns 17,656 shares of the company’s stock valued at $471,000 after buying an additional 1,411 shares during the period. Royal Bank of Canada raised its position in Catalent by 81.5% in the first quarter. Royal Bank of Canada now owns 34,988 shares of the company’s stock valued at $933,000 after buying an additional 15,706 shares during the period. Envestnet Asset Management Inc. raised its position in Catalent by 45.2% in the first quarter. Envestnet Asset Management Inc. now owns 38,974 shares of the company’s stock valued at $1,039,000 after buying an additional 12,141 shares during the period. Finally, UBS Group AG raised its position in Catalent by 1.1% in the first quarter. UBS Group AG now owns 66,308 shares of the company’s stock valued at $1,769,000 after buying an additional 712 shares during the period. Institutional investors own 99.72% of the company’s stock.
Catalent Company Profile
Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.